British Journal of Dermatology

Cover image for Vol. 175 Issue 5

Early View (Online Version of Record published before inclusion in an issue)

Editor: Alex Anstey, Bangor, UK

Impact Factor: 4.317

ISI Journal Citation Reports © Ranking: 2015: 5/61 (Dermatology)

Online ISSN: 1365-2133

Associated Title(s): Clinical and Experimental Dermatology

VIEW

  1. 1 - 100
  2. 101 - 102
  1. Research Letters

    1. You have full text access to this OnlineOpen article
  2. Clinical Trials

    1. Histological examination confirms clinical clearance of actinic keratoses following treatment with ingenol mebutate 0·05% gel

      M. Ulrich, U. Reinhold, T. Skov, R. Elvang Søndergaard and P. Guitera

      Version of Record online: 7 DEC 2016 | DOI: 10.1111/bjd.14968

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Ingenol mebutate treats the deeper layers of the epidermis and the observed clinical clearance is not just a superficial effect.

      What does this study add?

      • This study confirms that clinical clearance correlates with histopathological clearance.
      • Agreement between reflectance confocal microscopy and histopathological diagnosis of clear skin was high, indicating that diagnosis of clearance using reflectance confocal microscopy may preclude the need for histopathological assessment and invasive biopsies.
  3. Research Letters

    1. Predictive phenotyping of inherited ichthyosis by next-generation DNA sequencing

      R. Saito, A. Boyce, C.-K. Hsu, E. Rashidghamat, M. Hide, E.K. Wedgeworth, C. Flohr, J.E. Mellerio and J.A. McGrath

      Version of Record online: 7 DEC 2016 | DOI: 10.1111/bjd.14807

      • image
      • image
  4. Systematic Reviews

    1. A systematic review of patient-reported outcomes in patients with cutaneous lupus erythematosus

      M.E. Ogunsanya, S.J. Kalb, A. Kabaria and S. Chen

      Version of Record online: 7 DEC 2016 | DOI: 10.1111/bjd.14868

      • image

      What's already known about this topic?

      • Cutaneous lupus erythematosus (CLE) is a chronic, dermatological autoimmune disease.
      • Health-related quality of life (HRQoL) in patients with CLE is severely impaired.

      What does this study add?

      • There are several modifiable and nonmodifiable factors associated with the poor HRQoL observed in patients with CLE.
      • While all of the patient-reported outcome measures used in patients with CLE are applicable, they were not all developed with input from patients with CLE.
  5. Research Letters

    1. Patients with chronic cold urticaria may benefit from doxycycline therapy

      M. Gorczyza, N. Schoepke, K. Krause, T. Hawro and M. Maurer

      Version of Record online: 7 DEC 2016 | DOI: 10.1111/bjd.14820

      • image
      • image
    2. Complement in bullous pemphigoid: results from a large observational study

      T.R. Romeijn, M.F. Jonkman, C. Knoppers, H.H. Pas and G.F.H. Diercks

      Version of Record online: 7 DEC 2016 | DOI: 10.1111/bjd.14822

    3. Comparisons of patients’ satisfaction should take expectations into account

      M. Dizon, E. Linos, S.T. Arron, K. Abuabara, A.M. Ruiz de Luzuriaga, C. Jin, W.J. Boscardin and M.-M. Chren

      Version of Record online: 7 DEC 2016 | DOI: 10.1111/bjd.14755

      • image
  6. Case Reports

    1. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature

      L. Maintz, J. Wenzel, M. Irnich, H. Reinhard and T. Bieber

      Version of Record online: 2 DEC 2016 | DOI: 10.1111/bjd.14813

      • image
      • image
      • image

      What's already known about this topic?

      • The non-Langerhans cell histiocytosis juvenile xanthogranulomatosis (JXG) is usually a benign disease limited to the skin.
      • Only a few cases of often fatal systemic disease with at least two affected organs have been reported.
      • Treatment is controversial and no standard protocol is available.

      What does this study add?

      • The successful treatment of a case of JXG with involvement of the skin, central nervous system, liver and spleen with cytarabine and 2-chlorodeoxyadenosine.
  7. Clinical Trials

    1. Phototherapy using narrowband ultraviolet B and psoralen plus ultraviolet A is beneficial in steroid-dependent antihistamine-refractory chronic urticaria: a randomized, prospective observer-blinded comparative study

      A. Bishnoi, D. Parsad, K. Vinay and M.S. Kumaran

      Version of Record online: 1 DEC 2016 | DOI: 10.1111/bjd.14778

      • image
      • image
      • image

      What's already known about this topic?

      • Studies on the use of phototherapy in chronic urticaria are limited by smaller sample size, retrospective nature and lack of characterization of disease severity.

      What does this study add?

      • Randomized, observer-blinded comparative study demonstrating that phototherapy is effective in the treatment of steroid-dependent antihistamine-refractory chronic urticaria.
      • The efficacy of phototherapy is maintained beyond completion of phototherapy.
      • Both narrowband ultraviolet B and psoralen plus ultraviolet A (PUVA) significantly convert positive autologous serum skin test and autologous plasma skin test to negative post-treatment and PUVA also significantly reduces serum immunoglobulin E levels.
  8. Review Articles

    1. Topical herbal medicines for atopic eczema: a systematic review of randomized controlled trials

      Y. Thandar, A. Gray, J. Botha and A. Mosam

      Version of Record online: 30 NOV 2016 | DOI: 10.1111/bjd.14840

      • image
      • image

      What's already known about this topic?

      • Patients use topical complementary or alternative medicines to manage atopic eczema.
      • Objective evidence of efficacy and safety is lacking and is essential for clinicians and patients to make informed choices.

      What does this study add?

      • Of six studies that displayed superiority of treatment over placebo, only two studies, of liquorice gel and Hypericum perforatum, were considered to have a low risk of bias across all domains.
      • The promising effect of these two therapies for atopic eczema warrants continued research in well-designed studies.
  9. Letters to the Editor

  10. Scholarly Reviews

    1. Are neutrophilic dermatoses autoinflammatory disorders?

      T.K. Satoh, M. Mellett, E. Contassot and L.E. French

      Version of Record online: 30 NOV 2016 | DOI: 10.1111/bjd.15105

      • image
      • image

      What's already known about this topic?

      • Many inherited autoinflammatory diseases have characteristic skin manifestations composed of a neutrophil-rich cutaneous inflammatory infiltrate.

      • Neutrophilic dermatoses have similar clinical skin manifestations to inherited autoinflammatory diseases caused by overproduction of certain cytokines of the interleukin-1 family.

      What does this study add?

      • Certain unifying features of these disorders suggest that they are a cutaneous consequence of autoinflammation and may be considered as autoinflammatory diseases.

      • Some of these neutrophilic dermatoses may lack IL-1 as a triggering cytokine, but can still benefit from IL-1-targeted therapy.

  11. Letters to the Editor

    1. Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180

      A. Sakai, Y. Shimomura, O. Ansai, Y. Saito, K. Tomii, Y. Tsuchida, H. Iwata, H. Ujiie, H. Shimizu and R. Abe

      Version of Record online: 29 NOV 2016 | DOI: 10.1111/bjd.15111

      • image
      • image
  12. Medical Dermatology

    1. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring

      H. Alinia, S. Moradi Tuchayi, J.A. Smith, I.M. Richardson, N. Bahrami, S.C. Jaros, L.F. Sandoval, M.E. Farhangian, K.L. Anderson, K.E. Huang and S.R. Feldman

      Version of Record online: 29 NOV 2016 | DOI: 10.1111/bjd.15085

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • We already know that short-term adherence to topical medication is poor, but there is too little information about patients’ long-term use of treatment.
      • Understanding long-term adherence to topical treatment of chronic skin diseases is essential.

      What does this study add?

      • Long-term adherence to topical treatment is abysmal and measures that physicians can take to improve adherence have the potential to provide major improvements in patients’ treatment outcomes.
      • A reporting intervention can have large effects on short-term adherence, but effects on long-term adherence attenuate over time.
  13. General Dermatology

    1. A dynamic landscape of allergen associations in delayed-type cutaneous hypersensitivity

      M.D. Lynch, J.M. White, J.P. McFadden, Y. Wang, I.R. White and P. Banerjee

      Version of Record online: 29 NOV 2016 | DOI: 10.1111/bjd.14793

      • image
      • image
      • image

      What's already known about this topic?

      • Patients undergoing patch testing may exhibit positive test results to more than one allergen.
      • Positive results to specific pairs of allergens are associated.

      What does this study add?

      • We have identified 243 statistically significant pairwise allergen associations.
      • Allergen associations are highly dynamic and vary according to the date of testing, age, sex and atopy status.
      • There are statistically significant differences in the association of specific allergen pairs according to sex, age and atopy status.
  14. Research Letters

    1. Bacterial biofilm in acute lesions of hidradenitis suppurativa

      G.A. Okoye, N. Vlassova, O. Olowoyeye, A. Agostinho, G. James, P.S. Stewart, S. Leung and G. Lazarus

      Version of Record online: 26 NOV 2016 | DOI: 10.1111/bjd.14805

      • image
  15. General Dermatology

    1. Cross-reactivity between methylisothiazolinone, octylisothiazolinone and benzisothiazolinone using a modified local lymph node assay

      J.F. Schwensen, C. Menné Bonefeld, C. Zachariae, C. Agerbeck, T.H. Petersen, C. Geisler, U.E. Bollmann, K. Bester and J.D. Johansen

      Version of Record online: 26 NOV 2016 | DOI: 10.1111/bjd.14825

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Contact allergy to methylisothiazolinone (MI) in the European population is alarmingly high.

      • Retrospective observational studies of patients with contact allergy to MI have shown that concomitant reactions between MI, octylisothiazolinone (OIT) and benzisothiazolinone (BIT) may exist.

      What does this study add?

      • MI induced a significant concentration-dependent immune response after a sensitization phase of three consecutive days.
      • MI, OIT and BIT induced the same concentration-dependent inflammatory response with proliferation of CD4+ and CD8+ T cells, and partly CD19+ B cells, in MI-sensitized mice.
      • Cross-reactivity was seen between MI and OIT and between MI and BIT when the potency of the chemical was taken into account in the choice of challenge concentration.
  16. Translational Research

    1. You have full text access to this OnlineOpen article
      Increased epidermal thickness and abnormal epidermal differentiation in keloid scars

      G.C. Limandjaja, L.J. van den Broek, T. Waaijman, H.A. van Veen, V. Everts, S. Monstrey, R.J. Scheper, F.B. Niessen and S. Gibbs

      Version of Record online: 26 NOV 2016 | DOI: 10.1111/bjd.14844

      • image
      • image
      • image

      What's already known about this topic?

      • With regards to keloid scarring, the focus has always been on the dermal compartment when studying the underlying pathogenesis.
      • However, we know that epidermal–dermal interactions are essential in wound healing and, as such, the epidermis of keloid scars is worth further investigation.
      • While epidermal abnormalities have already been described in hypertrophic scars, the literature on the keloid epidermis remains inconclusive.

      What does this study add?

      • We show that keloids have increased epidermal thickness compared with normal skin and normotrophic and hypertrophic scars.
      • This was not due to hyperproliferation, but possibly caused by abnormal early terminal differentiation, which affects stratum corneum formation.

      What is the translational message?

      • Our findings indicate that the epidermis is associated with keloid pathogenesis and identify involucrin as a potential diagnostic marker for abnormal scarring.
  17. Medical Dermatology

    1. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

      K. Reich, A. Blauvelt, A. Armstrong, R.G. Langley, T. Fox, J. Huang, C. Papavassilis, E. Liang, P. Lloyd and G. Bruin

      Version of Record online: 22 NOV 2016 | DOI: 10.1111/bjd.14965

      • image
      • image
      • image

      What's already known about this topic?

      • The proinflammatory cytokine interleukin (IL)-17A plays a pivotal role in psoriasis pathogenesis.
      • Secukinumab is a therapeutic fully human monoclonal antibody that selectively targets IL-17A.
      • Secukinumab has demonstrated efficacy in phase III clinical trials of patients with moderate-to-severe psoriasis.
      • Biologics can be immunogenic, and the resulting antidrug antibodies can compromise efficacy.

      What does this study add?

      • Secukinumab demonstrated low immunogenicity, and the antidrug antibodies that were detected were of no clinical concern.
  18. General Dermatology

    1. You have full text access to this OnlineOpen article
      Concurrent beneficial (vitamin D production) and hazardous (cutaneous DNA damage) impact of repeated low-level summer sunlight exposures

      S.J. Felton, M.S. Cooke, R. Kift, J.L. Berry, A.R. Webb, P.M.W. Lam, F.R. de Gruijl, A. Vail and L.E. Rhodes

      Version of Record online: 18 NOV 2016 | DOI: 10.1111/bjd.14863

      • image
      • image
      • image

      What's already known about this topic?

      • Repeated low-level exposures to simulated U.K. sunlight can produce vitamin D sufficiency in light-skinned people, but the concurrent impact on cutaneous DNA damage is unknown.

      What does this study add?

      • Low-level simulated sunlight exposures in people of skin phototype II conferred vitamin D sufficiency concurrently with DNA damage, which showed partial clearance at 24 h and no evidence of accumulated damage after 6 weeks of exposures.
      • The same exposures produced minimal DNA damage but less vitamin D in brown-skinned people (phototype V).
      • The findings are informative for sun-exposure guidance.
  19. Research Letters

    1. Lymph node image-guided core-needle biopsy for cutaneous T-cell lymphoma staging

      M. Battistella, C. Sallé de Chou, C. de Bazelaire, J.M. Cayuela, E. de Kerviler, M. Bagot and A. Janin

      Version of Record online: 15 NOV 2016 | DOI: 10.1111/bjd.14850

      • image
    2. Trends in laboratory-diagnosed onychomycosis between 2006 and 2014 in the South West of England

      C. Wlodek, A. Trickey, D. de Berker and E.M. Johnson

      Version of Record online: 15 NOV 2016 | DOI: 10.1111/bjd.14804

  20. Clinical Trials

    1. You have full text access to this OnlineOpen article
      Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm®- and placebo-controlled trial (BRIDGE)

      U. Mrowietz, J.C. Szepietowski, R. Loewe, P. van de Kerkhof, R. Lamarca, W.G. Ocker, V.M. Tebbs and I. Pau-Charles

      Version of Record online: 15 NOV 2016 | DOI: 10.1111/bjd.14947

      • image
      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • A combination of fumaric acid esters (FAEs), including dimethyl fumarate (DMF), is approved for the treatment of moderate-to-severe psoriasis in Germany, with a positive risk–benefit profile for long-term use.
      • Despite being recommended in international treatment guidelines, FAEs are not available in most European countries.

      What does this study add?

      • This international, randomized, double-blind trial demonstrates the efficacy and safety of LAS41008 (DMF) for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
  21. General Dermatology

    1. Factors driving the use of dermoscopy in Europe: a pan-European survey

      A.M. Forsea, P. Tschandl, V. del Marmol, I. Zalaudek, H.P. Soyer, Eurodermoscopy Working Group, A.C. Geller and G. Argenziano

      Version of Record online: 15 NOV 2016 | DOI: 10.1111/bjd.14895

      • image

      What's already known about this topic?

      • Dermoscopy is a well-established tool for the noninvasive diagnosis of skin diseases.
      • The benefits of dermoscopy depend on correct use by trained physicians.
      • Although considered to be widely used in Europe, reports on dermoscopy use by dermatologists have been carried out in only two European countries so far.

      What does this study add?

      • Our study is the first pan-European survey of dermatologists regarding the patterns of use, training and attitudes towards dermoscopy.
      • We report on the demographic, practice- and training-related factors driving or hampering the use of dermoscopy in the daily practice of dermatologists in 32 European countries.
  22. Translational Research

    1. Functional assessment of tyrosinase variants identified in individuals with albinism is essential for unequivocal determination of genotype-to-phenotype correlation

      M. Mondal, M. Sengupta and K. Ray

      Version of Record online: 11 NOV 2016 | DOI: 10.1111/bjd.14977

      • image
      • image

      What's already known about this topic?

      • Oculocutaneous albinism (OCA) is a group of autosomal recessive disorders resulting from congenital hypopigmentation of ocular and cutaneous tissues.
      • Defects in the tyrosinase gene (TYR) are a major cause of OCA in many countries. Incidentally, OCA is a major cause of childhood blindness in India.
      • Limited experimental evidence suggests that retention of TYR in the endoplasmic reticulum (ER) is responsible for OCA1 pathogenesis.

      What does this study add?

      • This study reveals that ER retention of tyrosinase variant proteins is the principal cause of loss of enzyme activity.
      • The study clearly demonstrates that a functional assay of suspect TYR variants is essential to correlate genotype to phenotype in patients with OCA.
      • TYR single-nucleotide polymorphisms listed in dbSNP, specifically with low or no recorded frequency, could potentially be mutant alleles identified in phenotypically normal heterozygous individuals.

      What is the translational message?

      • Using OCA1 as a model disease, it is proposed that identification of rare or unique genetic variants in the causal gene of an inherited disease must be complemented with functional studies to implicate the suspect variants with the disease unequivocally.
      • For genetic diseases, correct determination of causal mutations has far-reaching implications for genetic counselling and/or prenatal diagnosis, as appropriate.
  23. Research Letters

    1. Vitiligo-like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre

      H.E. Teulings, J.E. Lommerts, A. Wolkerstorfer, L. Nieuweboer-Krobotova, R.M. Luiten, M.W. Bekkenk and J.P.W. van der Veen

      Version of Record online: 11 NOV 2016 | DOI: 10.1111/bjd.14790

    2. Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis

      C.C. Ang, C.O. Anyanwu, E. Robinson, J. Okawa, R. Feng, M. Fujimoto, Y. Hamaguchi and V.P. Werth

      Version of Record online: 11 NOV 2016 | DOI: 10.1111/bjd.14801

  24. Case Reports

    1. Severe recalcitrant cutaneous manifestations in systemic lupus erythematosus successfully treated with fumaric acid esters

      A.M. Saracino and C.H. Orteu

      Version of Record online: 6 NOV 2016 | DOI: 10.1111/bjd.14698

      • image
      • image
      • image

      What's already known about this topic?

      • Fumaric acid esters (FAEs) exert a variety of immunomodulatory, anti-inflammatory and antioxidant effects.
      • FAEs are an effective treatment for moderate-to-severe psoriasis and have been reported to be effective in treating other inflammatory and granulomatous skin diseases.

      What does this study add?

      • We report the efficacious and well-tolerated use of FAEs in the treatment of severe, extensive and recalcitrant cutaneous manifestations of systemic lupus erythematosus (SLE), previously treated unsuccessfully with several monotherapies and combination therapies.
      • These cases demonstrate the safe use of FAEs with concurrent immunomodulatory and immunosuppressive therapies in the context of treating SLE.
      • We report the first cases of chilblain lupus erythematosus treated with FAEs.
  25. Epidemiology

    1. You have full text access to this OnlineOpen article
      Statin use and the risk of herpes zoster: a nested case–control study using primary care data from the U.K. Clinical Research Practice Datalink

      A. Matthews, M. Turkson, H. Forbes, S.M. Langan, L. Smeeth and K. Bhaskaran

      Version of Record online: 2 NOV 2016 | DOI: 10.1111/bjd.14815

      • image
      • image

      What's already known about this topic?

      • Studies in both Canada and Taiwan have recently reported a small but significantly increased risk of herpes zoster (HZ) in patients receiving statin treatment.
      • As statins are one of the most widely prescribed drugs in the U.K., with around 45 million prescriptions every year, any adverse effects will have substantial public health implications.

      What does this study add?

      • In this large matched case–control study, statin exposure was associated with a modest increase in the risk of HZ.
      • A dose–response relationship was observed, and there was an attenuation of the increased risk over time among people who stopped statin therapy, indicating that the increased risk is consistent with a causal effect.
      • There may be extra motivation to maximize HZ vaccine uptake among eligible patients receiving a statin.
    2. Rosacea and gastrointestinal disorders: a population-based cohort study

      A. Egeberg, L.B. Weinstock, E.P. Thyssen, G.H. Gislason and J.P. Thyssen

      Version of Record online: 31 OCT 2016 | DOI: 10.1111/bjd.14930

      • image
      • image

      What's already known about this topic?

      • Rosacea is a common skin disorder, affecting 5–10% of Caucasians.
      • Patients with rosacea frequently report gastrointestinal symptoms.

      What does this study add?

      • Rosacea is significantly associated with coeliac disease, Crohn disease, ulcerative colitis, irritable bowel syndrome, and in some Helicobacter pylori infections, and may serve as a diagnostic marker of unrecognized gastrointestinal disease.
    3. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A.

      Z. Ren, D.Y. Hsu, J. Brieva, N.B. Silverberg, S.M. Langan and J.I. Silverberg

      Version of Record online: 29 OCT 2016 | DOI: 10.1111/bjd.14821

      • image
      • image

      What's already known about this topic?

      • Bullous pemphigoid is associated with considerable morbidity.
      • The inpatient comorbidities and mortality of bullous pemphigoid have not been well described.

      What does this study add?

      • The present study revealed novel associations between bullous pemphigoid and numerous neuropsychiatric, cardiovascular and infectious comorbidities in adults.
      • Mortality rates for adults with a secondary diagnosis of bullous pemphigoid were higher than for those without bullous pemphigoid.
  26. Letters to the Editor

    1. Home self-administration of omalizumab for chronic spontaneous urticaria

      S. Denman, K. Ford, J. Toolan, A. Mistry, C. Corps, P. Wood and S. Savic

      Version of Record online: 27 OCT 2016 | DOI: 10.1111/bjd.15074

      • image
    2. Frontal fibrosing alopecia: there is no statistically significant association with leave-on facial skin care products and sunscreens

      S.D. Seegobin, C. Tziotzios, C.M. Stefanato, K. Bhargava, D.A. Fenton and J.A. McGrath

      Version of Record online: 26 OCT 2016 | DOI: 10.1111/bjd.15054

    3. Frontal fibrosing alopecia: there is no statistically significant association with leave-on facial skin care products and sunscreens: reply from the authors

      N. Aldoori, K. Dobson, C.R. Holden, A.J. McDonagh, M. Harries and A.G. Messenger

      Version of Record online: 26 OCT 2016 | DOI: 10.1111/bjd.15056

  27. Research Letters

  28. Case Reports

    1. Multiple apocrine hidrocystomas successfully treated with botulinum toxin A

      J.R. Bordelon, N. Tang, D. Elston, G. Niedt and T. Lazic Strugar

      Version of Record online: 26 OCT 2016 | DOI: 10.1111/bjd.14753

      • image
      • image
      • image

      What's already known about this topic?

      • Current treatments for solitary hidrocystomas, both eccrine and apocrine, are numerous and usually efficacious.
      • Treatments for multiple hidrocystomas are more challenging and often limited due to surface area and location.
      • Recently, botulinum toxin A (BTX-A) has been successfully used for the treatment of multiple eccrine hidrocystomas; the possible mechanism may be denervation of the cholinergic eccrine glands.

      What does this study add?

      • There are some data to suggest that apocrine glands are innervated similarly to eccrine glands, and we therefore propose treating apocrine hidrocystomas with BTX-A via the same mechanism.
      • This case portrays the successful use of BTX-A in the treatment of multiple facial apocrine hidrocystomas, leading to lesion resolution.
  29. Research Letters

    1. Dermoscopic findings of vulvar intraepithelial neoplasia: a series of four cases

      A. Barisani, E. Dika, P.A. Fanti, P. De Iaco, G. Tosti, A. Patrizi and S. Vaccari

      Version of Record online: 25 OCT 2016 | DOI: 10.1111/bjd.14796

      • image
      • image
      • image
      • image
    2. Transcriptomic analysis of skin in a case of ichthyosis Curth–Macklin caused by a KRT1 mutation

      O. Ortega-Recalde, D. Silgado, C. Fetiva, D.J. Fonseca and P. Laissue

      Version of Record online: 23 OCT 2016 | DOI: 10.1111/bjd.14969

      • image
  30. Case Reports

    1. PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma

      J.K. Winkler, C. Bender, C. Kratochwil, A. Enk and J.C. Hassel

      Version of Record online: 23 OCT 2016 | DOI: 10.1111/bjd.14632

      • image
      • image

      What's already known about this topic?

      • Immune escape mechanisms are involved in the progression of Merkel cell carcinoma (MCC).
      • Preliminary results have been obtained from a phase II trial evaluating pembrolizumab for the treatment of MCC.
      • Complete response to pembrolizumab has been observed for a patient with MCC (phase I trial).

      What does this study add?

      • Positron emission computed tomography evaluation revealed a significant response to treatment with pembrolizumab.
      • Resumption of pembrolizumab after disease progression was successful.
      • Programmed death ligand 1 expression and immune infiltration were assessed histologically.
  31. Research Letters

    1. Clinical and dermoscopic features of lichen planus pigmentosus in 37 patients with frontal fibrosing alopecia

      R. Pirmez, B. Duque-Estrada, A. Donati, G. Campos-do-Carmo, N.S. Valente, R. Romiti, C.T. Sodré and A. Tosti

      Version of Record online: 23 OCT 2016 | DOI: 10.1111/bjd.14722

      • image
  32. Review Articles

    1. Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review

      J.G. Schlager, S. Rosumeck, R.N. Werner, A. Jacobs, J. Schmitt, C. Schlager and A. Nast

      Version of Record online: 19 OCT 2016 | DOI: 10.1111/bjd.14811

      • image
      • image

      What's already known about this topic?

      • Patients with chronic plaque psoriasis often have lesions of the scalp that are difficult to treat.
      • There are various effective topical treatment options such as corticosteroids (e.g. betamethasone dipropionate), vitamin D (e.g. calcipotriol) and their combination.
      • Detailed Grading of Recommendations Assessment, Development and Evaluation Working Group assessment of the effect of these treatments has not been done so far.

      What does this study add?

      • Overall moderate-quality evidence that the two-compound combination is only of small benefit over the corticosteroid alone, and that both therapies are similarly safe (short-term therapy).
      • Overall moderate-quality evidence that the two-compound combination and corticosteroid monotherapy are more effective and safer than vitamin D alone (short-term therapy).
      • Firm conclusions for other topical treatments cannot be drawn due to limited data.
  33. Systematic Reviews

    1. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis

      S. Guillén-Aguinaga, I. Jáuregui Presa, E. Aguinaga-Ontoso, F. Guillén-Grima and M. Ferrer

      Version of Record online: 19 OCT 2016 | DOI: 10.1111/bjd.14768

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Antihistamines represent the first-line therapy for chronic spontaneous urticaria (CSU).
      • In spite of their efficacy, CSU remains uncontrolled in a high percentage of patients receiving regular doses of antihistamines.
      • Guidelines for the management of CSU recommend updosing antihistamines up to fourfold as a second-line therapy.

      What does this study add?

      • This is the first meta-analysis on updosing antihistamines for the treatment of CSU.
      • In spite of the high recommendation, updosing antihistamines significantly improves control of pruritus but not weal number.
      • There is a great need for large well-performed studies on this subject as the present studies that support updosing are relatively weak and have a high level of heterogeneity.
  34. Research Letters

    1. You have free access to this content
  35. Medical Dermatology

    1. Protoporphyrin IX in the skin measured noninvasively predicts photosensitivity in patients with erythropoietic protoporphyria

      I.M. Heerfordt and H.C. Wulf

      Version of Record online: 17 OCT 2016 | DOI: 10.1111/bjd.15050

      • image
      • image
      • image
      • image

      What's already known about the topic?

      • Erythropoietic protoporphyria (EPP) causes severe sensitivity to light owing to the accumulation of protoporphyrin IX (PpIX) in the skin.
      • Currently, there is no noninvasive method for measuring PpIX in the skin.

      What does this study add?

      • Skin PpIX can be measured noninvasively as the difference in PpIX fluorescence before and after controlled illumination.
      • PpIX in the skin of patients with EPP was associated with erythrocyte PpIX, skin erythema and the onset of symptoms during illumination.
  36. Research Letters

    1. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer

      J.K. Winkler, R. Schneiderbauer, C. Bender, O. Sedlaczek, S. Fröhling, R. Penzel, A. Enk and J.C. Hassel

      Version of Record online: 17 OCT 2016 | DOI: 10.1111/bjd.14664

      • image
      • image
      • image
      • image
  37. Letters to the Editor

    1. Association between rosacea and gastrointestinal disorders

      A. Alexoudi, I. Alexoudi and S. Gatzonis

      Version of Record online: 17 OCT 2016 | DOI: 10.1111/bjd.15052

  38. Medical Dermatology

    1. Clinical and immunological studies of 49 cases of various types of intercellular IgA dermatosis and 13 cases of classical subcorneal pustular dermatosis examined at Kurume University

      T. Hashimoto, K. Teye and N. Ishii

      Version of Record online: 17 OCT 2016 | DOI: 10.1111/bjd.14780

      • image

      What's already known about this topic?

      • There is a subset of autoimmune bullous disease, exclusively with IgA antikeratinocyte cell-surface antibodies, called intercellular IgA dermatosis or IgA pemphigus.
      • Because of a lack of systematic study, the classification and pathogenesis of this condition are still obscure.

      What does this study add?

      • This is the largest study to date, with our cohort of 49 cases of intercellular IgA dermatosis.
      • We propose a classification with five subtypes.
      • Major autoantigens in intercellular IgA dermatosis are desmocollins and desmogleins, although antigens are not determined in many cases.
  39. Translational Research

    1. Immune cells from patients with psoriasis are defective in inducing indoleamine 2,3-dioxygenase expression in response to inflammatory stimuli

      M. Llamas-Velasco, P. Bonay, M. José Concha-Garzón, L. Corvo-Villén, A. Vara, D. Cibrián, A. Sanguino-Pascual, F. Sánchez-Madrid, H. de la Fuente and E. Daudén

      Version of Record online: 17 OCT 2016 | DOI: 10.1111/bjd.14779

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Data regarding indoleamine 2,3-dioxygenase (IDO) regulation in human autoimmune diseases are limited.
      • In psoriasis, IDO expression has been studied only in lesional skin.

      What does this study add?

      • This study demonstrates that in patients with psoriasis, IDO activity in serum samples is reduced as the disease severity increases.
      • Peripheral myeloid dendritic cells from patients with psoriasis fail to induce IDO in response to inflammatory stimuli.
      • Induction of CD4+ regulatory T-cell differentiation by immature monocyte-derived dendritic cells from patients with psoriasis is reduced and is associated with a lower expression of IDO.

      What is the translational message?

      • IDO activity measured in serum samples, as well as its expression induced by proinflammatory stimuli, is associated with higher Psoriasis Area and Severity Index.
      • A lower expression of IDO is also associated with a defective differentiation of regulatory T cells.
      • These data provided a better understanding of the exacerbated inflammatory response characteristic of this condition, and suggest that IDO may be a therapeutic target for psoriasis.
  40. Research Letters

    1. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort

      D. Ruiz-Genao, B. Perez-Zafrilla, J.L. Lopez-Estebaranz, I. Belinchón-Romero, J.M. Carrascosa, M. Ferrán, F. Vanaclocha, E. Herrera-Ceballos, I. García-Doval and The Biobadaderm Study Group

      Version of Record online: 17 OCT 2016 | DOI: 10.1111/bjd.14690

  41. Case Reports

    1. Small-fibre neuropathy in a patient with dermatomyositis and severe scalp pruritus

      E. Hurliman, D. Groth, G. Wendelschafer-Crabb, W. Kennedy, S. Kavand, M. Ericson and M. Hordinsky

      Version of Record online: 13 OCT 2016 | DOI: 10.1111/bjd.14678

      • image

      What's already known about this topic?

      • It is known that pruritus is a complex and multifactorial phenomenon. Dermatomyositis is a condition that is commonly associated with recalcitrant treatment-resistant pruritus.

      What does this study add?

      • This study adds to the existing knowledge by demonstrating abnormal epidermal nerve fibre structure that may be related to the severe pruritus associated with dermatomyositis.
  42. Research Letters

    1. Towards three-dimensional temporal monitoring of naevi: a comparison of methodologies for assessing longitudinal changes in skin surface area around naevi

      E. Chung, M.A. Marchetti, A. Scope, S.W. Dusza, M. Fonseca, D. DaSilva, S. Bajaj, A.C. Geller, M. Bishop, A.A. Marghoob and A.C. Halpern

      Version of Record online: 13 OCT 2016 | DOI: 10.1111/bjd.14700

      • image
      • image
  43. Systematic Reviews

    1. Short-term efficacy and safety of new biological agents targeting the interleukin-23–T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis

      F. Gómez-García, D. Epstein, B. Isla-Tejera, A. Lorente, A. Vélez García-Nieto and J. Ruano

      Version of Record online: 13 OCT 2016 | DOI: 10.1111/bjd.14814

      • image
      • image

      What's already known about this topic?

      • Old antitumour necrosis factor-α agents and recently licensed drugs blocking the interleukin-23–T helper 17 pathway are more efficacious than placebo for the treatment of moderate-to-severe plaque psoriasis.
      • Traditionally, meta-analyses have usually compared only two interventions at a time, but the need to summarize a comprehensive and coherent set of comparisons based on all of the available evidence has led more recently to synthetic methods that address multiple interventions.

      What does this study add?

      • To the best of our knowledge, this is the first network meta-analysis to study the comparative short-term efficacy and safety of these agents using the new 2015 PRISMA statement for network meta-analyses.
      • Infliximab and secukinumab ranked as the most efficacious drugs, but with the highest risk for any adverse event and associated infections, respectively.
      • Ustekinumab was the agent with the best efficacy–safety profile.
  44. Epidemiology

    1. Risk of skin cancer in patients on chronic haemodialysis: a nationwide, population-based study in Taiwan

      C.-C. Wang, C.-H. Tang, C.-Y. Wang, S.-Y. Huang and Y.-M. Sue

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bjd.14789

      • image
      • image

      What's already known about this topic?

      • Patients on chronic haemodialysis have a higher incidence of cancers, particularly those of the kidney, urinary tract and thyroid.

      What does this study add?

      • Patients on chronic haemodialysis carry a higher risk for nonmelanoma skin cancer (NMSC).
      • Uraemic pruritus with long-term antihistamine treatment further increases the risk of NMSC.
      • Ultraviolet B phototherapy might reduce the cutaneous inflammatory status of uraemic pruritus, thereby diminishing the risk of NMSC.
  45. Systematic Reviews

    1. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis

      F.M. Ali, A.C. Cueva, J. Vyas, A.A. Atwan, M.S. Salek, A.Y. Finlay and V. Piguet

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bjd.14788

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Psoriasis significantly impacts quality of life (QoL) in patients.
      • Generic, skin-specific and disease-specific instruments are used in psoriasis interventional studies.
      • In psoriasis randomized controlled trials (RCTs), biologics are the most researched interventions for which QoL is reported.

      What does this study add?

      • The most commonly used QoL instruments in psoriasis RCTs are the Dermatology Life Quality Index, 36-Item Short Form Survey and EuroQol-5D.
      • There is an increasing use of QoL instruments in RCTs in psoriasis.
      • The minimal clinically important difference of QoL measure scores is under-reported.
      • There is inconsistent reporting of QoL data and a need for guidelines when reporting.
  46. Translational Research

    1. Expression pattern of the CXCL12/CXCR4–CXCR7 trio in Kaposi sarcoma skin lesions

      A. Desnoyer, N. Dupin, L. Assoumou, A. Carlotti, F. Gaudin, C. Deback, G. Peytavin, A.G. Marcelin, F. Boué, K. Balabanian, V. Pourcher and the ANRS 154 LENAKAP trial group

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bjd.14748

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Chemokines play important roles in the pathogenesis of Kaposi sarcoma (KS).
      • Recent studies have independently implicated CXCL12, CXCR4 and CXCR7 in KS pathophysiology.

      What does this study add?

      • We observed a simultaneous CXCL12/CXCR4–CXCR7 upregulation in AIDS-associated KS and classic KS lesions that correlates with both the lesion severity and detection of latency-associated nuclear antigen, Ki67 and vascular endothelial growth factor.
      • The detection of the CXCL12/CXCR4–CXCR7 trio could be used as a tissue biomarker for KS lesions.

      What is the translational message?

      • The CXCL12 axis has been shown to be involved in chronic skin inflammation and inflammatory angiogenesis; two components of KS pathogenesis.
      • Histological detection of the CXCL12 axis could allow KS classification, patient stratification or KS progression prediction.
      • Targeting the CXCL12 signalling axis might serve as a novel therapeutic strategy for KS.
  47. General Dermatology

    1. Dermoscopy and in vivo confocal microscopy are complementary techniques for diagnosis of difficult amelanotic and light-coloured skin lesions

      P. Guitera, S.W. Menzies, G. Argenziano, C. Longo, A. Losi, M. Drummond, R.A. Scolyer and G. Pellacani

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bjd.14749

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Because of their lack of pigment, amelanotic melanomas are more difficult to diagnose than pigmented lesions, and they have a worse prognosis.

      What does this study add?

      • The amelanotic dermoscopy method had the highest sensitivity but lowest specificity. Reflectance confocal microscopy reader confidence was higher than that of the dermoscopy reader. All melanomas missed by one tool were detected by the other.
  48. Case Reports

    1. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition

      P. Skendros, C. Papagoras, I. Lefaki, A. Giatromanolaki, I. Kotsianidis, M. Speletas, V. Bocly, I. Theodorou, V. Dalla and K. Ritis

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bjd.14685

      • image

      What's already known about this topic?

      • Generalized pustular psoriasis (GPP) is an inflammatory dermatological disorder accompanied by severe systemic complications.
      • Genetic studies and reports of favourable response to IL-1 blockade strongly implicate the IL-1 family in the pathophysiology of GPP.

      What does this study add?

      • This is the first report of a complete and sustained response of GPP to the anti-IL-1β monoclonal antibody canakinumab.
      • Randomized control trials with IL-1 inhibitors in severe pustular and erythodermic psoriasis are encouraged.
  49. Epidemiology

    1. Increased overall drug utilization in patients with psoriasis: a case–control study based on Dutch general practitioner data

      E.A. Dowlatshahi, L.M. Hollestein, R.M.C. Herings, T. Nijsten and M. Wakkee

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bjd.14754

      • image

      What's already known about this topic?

      • Patients with psoriasis use more health resources than people without psoriasis.
      • Medication use in psoriasis has been studied mostly in the context of psoriasis comorbidities.

      What does this study add?

      • This is the first large population-based study to give an overview of the entire spectrum of drug use in patients with psoriasis compared with controls, during a long follow-up period.
      • The findings suggest increased healthcare utilization among patients with psoriasis.
  50. Research Letters

    1. Evaluation of pharyngo-oesophageal involvement in pemphigus vulgaris and its correlation with disease activity

      A. Okamura, R. Nakamura, J. Yamagami, K. Ishii, H. Kawakubo, T. Omori, H. Takeuchi, M. Amagai and Y. Kitagawa

      Version of Record online: 12 OCT 2016 | DOI: 10.1111/bjd.14725

      • image
    2. Hyperpigmentation following the Blaschko's lines: a subtle cutaneous manifestation of Turner syndrome with complex mosaicism

      G. Deza, D. López Aventín, M. Salido, B. Espinet, M. Gilaberte and R.M. Pujol

      Version of Record online: 7 OCT 2016 | DOI: 10.1111/bjd.14688

      • image
  51. General Dermatology

    1. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort

      J. Zweegers, B. Roosenboom, P.C.M. van de Kerkhof, J.M.P.A. van den Reek, M.E. Otero, S. Atalay, A.L.A. Kuijpers, M.I.A. Koetsier, W.P. Arnold, M.A. Berends, L. Weppner-Parren, M. Bijen, M.D. Njoo, J.M. Mommers, P.P.M. van Lümig, R.J.B. Driessen, W. Kievit and E.M.G.J. de Jong

      Version of Record online: 7 OCT 2016 | DOI: 10.1111/bjd.14888

      • image

      What's already known about this topic?

      • A high clinical response in patients with psoriasis is shifting towards a 90% improvement compared with baseline Psoriasis Area and Severity Index (PASI 90).
      • To date, no studies have assessed which patients with psoriasis are more likely to achieve a high clinical response at week 24 of biological treatment.

      What does this study add?

      • We focused on high responders, defined as achieving PASI 100, PASI 90 or PASI ≤ 5.
      • Frequency of reaching high clinical responses at 24 weeks of biological treatment was assessed, as were predictors that could identify patients with the ability to respond well to biological treatment.
      • In only a limited number of treatment episodes are PASI 90 (15%) or PASI 100 (3%) achieved.
      • Lower baseline body mass index is a predictor for achieving PASI ≤ 5.
  52. Translational Research

    1. Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema

      V. Kumari, K. Timm, A.A. Kühl, G. Heine and M. Worm

      Version of Record online: 7 OCT 2016 | DOI: 10.1111/bjd.14921

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Severe hand eczema is a frequent skin disease and creates a significant socioeconomic burden.
      • Alitretinoin has been shown to be effective in treating chronic hand eczema (CHE).
      • Retinoids modulate the proliferation and differentiation of keratinocytes.

      What does this study add?

      • Systemic alitretinoin treatment results in normalization of a disrupted skin barrier gene and protein expression.
      • The expression levels of several barrier genes correlate significantly with the clinical severity in hand eczema.
      • Thymic stromal lymphopoietin expression is increased in CHE and correlates negatively with filaggrin expression.

      What is the translational message?

      • Systemic alitretinoin treatment normalizes barrier gene and protein expression in CHE.
  53. Letters to the Editor

    1. Chemoprevention of basal cell carcinoma: reply from authors

      I. Hoorens and L. Brochez

      Version of Record online: 7 OCT 2016 | DOI: 10.1111/bjd.15055

    2. Chemoprevention of basal cell carcinoma

      F.R. Ali, E.E. Craythorne and F. Al-Niaimi

      Version of Record online: 6 OCT 2016 | DOI: 10.1111/bjd.14937

    3. Incidence and risk factors of blood splatter in dermatological surgery: how protective are full facial masks?

      S. Aguilar-Duran, A. Panthagani, L. Naysmith and S. A. Holme

      Version of Record online: 6 OCT 2016 | DOI: 10.1111/bjd.15009

  54. Translational Research

    1. Psoriasin (S100A7) promotes stress-induced angiogenesis

      J. Vegfors, A.-K. Ekman, S.W. Stoll, C. Bivik Eding and C. Enerbäck

      Version of Record online: 5 OCT 2016 | DOI: 10.1111/bjd.14718

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Psoriasis is characterized by extensive new blood vessel formation.
      • Early microvascular modifications in the psoriatic lesion have received limited attention in psoriasis pathogenesis.

      What does this study add?

      • Psoriasin expression is promoted by reactive oxygen species (ROS) and hypoxia in keratinocytes. It regulates the ROS-induced expression of several psoriasis-associated angiogenic factors, and acts on dermal endothelial cells to promote key features of the angiogenic process.

      What is the translational message?

      • Our data raise the possibility that psoriasin may be evaluated as a novel antiangiogenic target in psoriasis.
  55. Epidemiology

    1. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

      I. García-Doval, M.V. Hernández, F. Vanaclocha, A. Sellas, P. de la Cueva, D. Montero and the BIOBADADERM and BIOBADASER study groups

      Version of Record online: 3 OCT 2016 | DOI: 10.1111/bjd.14776

      What's already known about this topic?

      • Safety results from the use of biologics in some immune-mediated inflammatory diseases, such as rheumatoid arthritis, are frequently applied to others, such as psoriasis.

      What does this study add?

      • Safety results from studies of rheumatoid arthritis patients are not fully applicable to psoriasis patients, as the rate of serious adverse events in rheumatoid arthritis patients is almost double, and the pattern of adverse events is different.
  56. Letters to the Editor

  57. Case Reports

    1. Mosaic-activating FGFR2 mutation in two fetuses with papillomatous pedunculated sebaceous naevus

      P. Kuentz, S. Fraitag, M. Gonzales, F. Dhombres, J. St-Onge, Y. Duffourd, N. Joyé, J.-M. Jouannic, A. Picard, N. Marle, J. Thevenon, C. Thauvin-Robinet, L. Faivre, J.-B. Rivière and P. Vabres

      Version of Record online: 2 OCT 2016 | DOI: 10.1111/bjd.14681

      • image
      • image
      • image

      What's already known about this topic?

      • A rare subtype of papillomatous pedunculated sebaceous naevus (PPSN) has been reported in neonates and a fetus.
      • Most epidermal naevi have been associated with postzygotic mutations in genes encoding cell growth and proliferation signalling molecules: HRAS and KRAS in sebaceous naevi (SN), FGFR2 in acne or comedo naevi, and HRAS, KRAS, NRAS, FGFR3 and PIK3CA in keratinocytic epidermal naevi.

      What does this study add?

      • Here we report a novel postzygotic activating FGFR2 mutation in two unrelated fetuses with PPSN.
      • Mosaic receptor tyrosine kinase gene mutations, particularly in FGFR2, have not previously been reported in SN.
  58. Medical Dermatology

    1. You have full text access to this OnlineOpen article
      Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study

      K. Yamasaki, H. Nakagawa, Y. Kubo, K. Ootaki and the Japanese Brodalumab Study Group

      Version of Record online: 2 OCT 2016 | DOI: 10.1111/bjd.14702

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • The pathological roles of interleukin (IL)-17 cascades in severe types of psoriasis including generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) have not been well established.

      What does this study add?

      • Brodalumab significantly improved the symptoms of patients with GPP and PsE throughout the 52 weeks and demonstrated favourable safety profiles without any new safety signals.
      • Brodalumab is expected to be a promising new treatment option for patients with GPP and PsE by blocking IL-17-receptor A-mediated signalling.
  59. Letters to the Editor

  60. Review Articles

    1. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis

      F. Petrelli, K. Borgonovo, M. Cabiddu, A. Coinu, M. Ghilardi, V. Lonati and S. Barni

      Version of Record online: 30 SEP 2016 | DOI: 10.1111/bjd.14756

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Antiepidermal growth factor receptor drugs are used for cancer therapy.

      • They are associated with prevention of skin rash and may be useful to decrease the severity of toxicity. Oral antibiotics are sometimes suggested as preventive measures.

      What does this study add?

      • We have reviewed all published trials about antibiotic prophylaxis.

      • We confirm that tetracyclines are able to reduce the incidence of skin rash by 50%.

  61. Research Letters

  62. Letters to the Editor

    1. You have full text access to this OnlineOpen article
      Mutations in POGLUT1 in Galli–Galli/Dowling–Degos disease

      N.J. Wilson, C. Cole, K. Kroboth, W.N. Hunter, J.A. Mann, W.H.I. McLean, K. Kernland Lang, H. Beltraminelli, R.A. Sabroe, N. Tiffin, G.J. Sobey, L. Borradori, E. Simpson and F.J.D. Smith

      Version of Record online: 24 SEP 2016 | DOI: 10.1111/bjd.14914

      • image
      • image
  63. General Dermatology

    1. Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases

      H.M. Cheng, S. Lo, R. Scolyer, A. Meekings, G. Carlos and P. Guitera

      Version of Record online: 24 SEP 2016 | DOI: 10.1111/bjd.14714

      • image
      • image
      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Optical coherence tomography (OCT) can be used for diagnosis and depth measurement of basal cell carcinoma (BCC).
      • OCT features of subtypes of basal cell carcinoma have been described.

      What does this study add?

      • The clinical diagnostic accuracy of sBCC can be increased by the use of OCT.
      • The depth of thin BCCs < 0·4 mm can be measured accurately using OCT.
      • There is good interobserver agreement for sBCC diagnosis by OCT when performed by experienced operators.
      • More research is necessary before it would be appropriate to recommend its use as a substitute for pathology in diagnosis and management.
  64. Case Reports

    1. Foreign body reaction triggered by cytotoxic T lymphocyte-associated protein 4 blockade 25 years after dermal filler injection

      C. Bisschop, M.S. Bruijn, M.W. Stenekes, G.F.H. Diercks and G.A.P. Hospers

      Version of Record online: 24 SEP 2016 | DOI: 10.1111/bjd.14674

      • image
      • image

      What's already known about this topic?

      • Foreign body granuloma is regularly seen as a late complication of cosmetic treatment with synthetic dermal fillers.
      • Most often a severe systemic infection is the trigger of a foreign body reaction to dermal fillers. Autoimmune diseases and (immunostimulatory) drugs are known triggers.

      What does this study add?

      • Ipilimumab, an immune checkpoint inhibitor used as anticancer treatment, can cause a foreign body reaction to dermal filler treatment.
  65. General Dermatology

    1. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment

      J.M. Gonzalez, F.R. Johnson, H. McAteer, J. Posner and F. Mughal

      Version of Record online: 24 SEP 2016 | DOI: 10.1111/bjd.14798

      • image
      • image
      • image

      What's already known about this topic?

      • Plaque psoriasis is associated with a number of comorbidities and can have a significant negative effect on patients’ quality of life.
      • Systemic nonbiological and biological treatments for psoriasis can result in serious toxicities, including risks of serious infections and malignancies or lymphoma.

      What does this study add?

      • This study uses a discrete-choice experiment to elicit and contrast stated preferences for outcomes of psoriasis treatments from the perspective of patients with psoriasis and the dermatologists who treat them using a common instrument.
  66. Letters to the Editor

    1. The cross-talk between renal function, inflammation and psoriasis vulgaris

      S. Coimbra, H. Oliveira, P. Rocha-Pereira, A. Figueiredo and A. Santos-Silva

      Version of Record online: 21 SEP 2016 | DOI: 10.1111/bjd.14913

      • image
  67. Translational Research

    1. Dual c-Jun N-terminal kinase–cyclin D1 and extracellular signal-related kinase–c-Jun disjunction in human melanoma

      G. Pathria, B. Garg, K. Garg, C. Wagner and S.N. Wagner

      Version of Record online: 20 SEP 2016 | DOI: 10.1111/bjd.14713

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • BRAF targeting in BRAF-mutated melanomas fails to achieve a sustained therapeutic response.
      • Previous work has shown this to be partially associated with its inability to downregulate c-Jun expression and activity.
      • c-Jun N-terminal Kinase (JNK) signalling positively regulates c-Jun and its transcriptional target cyclin D1.

      What does this study add?

      • The current work demonstrates the requirement of JNK signalling in melanoma cell proliferation and survival.
      • JNK blockade, while successfully suppressing c-Jun expression/activity, fails to mitigate cyclin D1 levels.
      • MEK inhibition, although failing to suppress c-Jun expression/activity, successfully downregulated cyclin D1 levels.
      • This forms a further mechanistic basis for evaluating dual JNK/MEK–ERK signalling inhibition in BRAF-mutated melanomas.

      What is the translational message?

      • MAPK (MEK–ERK) and JNK signalling pathway inhibition, paradoxically, fails to suppress c-Jun and cyclin D1, respectively.
      • Suppression of c-Jun and cyclin D1 upon JNK and MEK–ERK pathway inhibition, respectively, seems intact in melanoma cells.
      • Together these observations purport concomitant MEK–ERK and JNK signalling pathway blockade as a potential therapeutic strategy in human melanoma.
  68. Research Letters

    1. Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial

      A.C. Chen, A.J. Martin, R.A. Dalziell, G.M. Halliday and D.L. Damian

      Version of Record online: 20 SEP 2016 | DOI: 10.1111/bjd.14648

      • image
    2. Ivermectin cream improves health-related quality of life in patients with rosacea: data from a randomized trial

      A. Taieb, T. Passeron, T. Ruzicka, J. Berth-Jones, J. Jacovella, M.Y. Huang and A. Wertheimer

      Version of Record online: 19 SEP 2016 | DOI: 10.1111/bjd.14665

      • image
  69. Translational Research

    1. The prognostic significance and impact of the CXCR4–CXCR7–CXCL12 axis in primary cutaneous melanoma

      A.T. McConnell, R. Ellis, B. Pathy, R. Plummer, P.E. Lovat and G. O'Boyle

      Version of Record online: 13 SEP 2016 | DOI: 10.1111/bjd.14720

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • CXCR4 expression is associated with poor prognostic indicators including tumour ulceration, thickness and metastasis.
      • Expression of CXCR4 is crucial in regulating melanoma chemotaxis to distant secondary sites of metastasis with high expression of the ligand, CXCL12.
      • Previous studies suggest a lack of correlation between melanoma CXCL12 expression and disease progression or BRAF mutational status.
      • CXCR7 is an atypical/decoy CXCL12 receptor that may act to shape CXCL12 gradients.

      What does this study add?

      • Elevated CXCR4 expression is a prognostic biomarker for AJCC stage II primary melanomas.
      • Autocrine melanoma CXCR4–CXCL12 signalling promotes hyperactivation of prosurvival MAPK signalling.
      • CXCL12 expression by stromal cells in the primary melanoma microenvironment protects from metastasis potentially by retaining tumour cells within the cutaneous microenvironment.
      • Downregulation of melanoma CXCL12 is associated with an aggressive BRAF/NRAS mutant phenotype.
      • CXCR7 expression by cutaneous vascular endothelium and not primary melanomas suggests a mechanism mediating tumour intravasation.

      What is the translational message?

      • CXCR4 expression defines a potential candidate biomarker for melanoma providing additional prognostic information to AJCC disease staging and a means of identifying high-risk patient subgroups.
      • The reported role of CXCR4–CXCR7–CXCL12 chemokine signalling within the primary cutaneous melanoma microenvironment highlights the potential for targeting this chemokine axis to prevent the development of metastatic disease.
  70. Letters to the Editor

  71. Medical Dermatology

    1. Overlap between maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms among cutaneous adverse drug reactions in a dermatology ward

      M. Pinto Gouveia, A. Gameiro, I. Coutinho, N. Pereira, J.C. Cardoso and M. Gonçalo

      Version of Record online: 6 SEP 2016 | DOI: 10.1111/bjd.14704

      • image
      • image

      What's already known about this topic?

      • Clinical patterns of nonimmediate cutaneous adverse drug reactions are well characterized, namely drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome/toxic epidermal necrolysis, acute generalized exanthematous pustulosis and maculopapular exanthema (MPE).
      • Occasional overlapping clinical patterns have been described.

      What does this study add?

      • We characterized an overlapping pattern between MPE and DRESS, with exanthema and less systemic involvement than DRESS.
      • Culprit drugs and affected organs were similar but with a reduced latency period and duration of the reaction, suggesting a minor form of DRESS.
  72. General Dermatology

    1. Consumer acceptance of patient-performed mobile teledermoscopy for the early detection of melanoma

      C. Horsham, L.J. Loescher, D.C. Whiteman, H.P. Soyer and M. Janda

      Version of Record online: 2 SEP 2016 | DOI: 10.1111/bjd.14630

      • image
      • image
      • image

      What's already known about this topic?

      • Cancer Councils recommend that patients conduct regular skin self-examinations for the early detection of melanoma.
      • Patient-initiated, self-performed mobile teledermoscopy may aid consumers in this process.

      What does this study add?

      • Older adults at high risk of melanoma are highly accepting of mobile teledermoscopy. However, complete trust in the telediagnosis was a concern among some participants.
      • Most participants found mobile teledermoscopy easy to conduct.
  73. Translational Research

    1. Identification of LCK mutation in a family with atypical epidermodysplasia verruciformis with T-cell defects and virus-induced squamous cell carcinoma

      S.-L. Li, L.-N. Duo, H.-J. Wang, W. Dai, E.-Y.H. Zhou, Y.-N. Xu, T. Zhao, Y.-Y. Xiao, L. Xia, Z.-H. Yang, L.-T. Zheng, Y.-Y. Hu, Z.-M. Lin, H.-N. Wang, T.-W. Gao, C.-L. Ma, Y. Yang and C.-Y. Li

      Version of Record online: 31 AUG 2016 | DOI: 10.1111/bjd.14679

      • image
      • image

      What's already known about this topic?

      • Epidermodysplasia verruciformis (EV) is an unusual genodermatosis characterized by an increased susceptibility to β-human papillomavirus and is associated with a high risk of skin carcinoma.
      • Inactivating mutations in EVER1/EVER2 account for most cases of EV.

      What does this study add?

      • Our study suggests an association between a novel splicing mutation in LCK and EV susceptibility.

      What is the translational message?

      • Patients with EV should be tested for T lymphocyte-specific protein tyrosine kinase deficiency and T-cell function, which will help guide treatment.
  74. Scholarly Reviews

    1. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review

      J. Callander, Y. Robson, J. Ingram and V. Piguet

      Version of Record online: 30 AUG 2016 | DOI: 10.1111/bjd.14726

      • image
      • image
      • image

      What's already known about this topic?

      • Clinically amyopathic dermatomyositis (CADM) is defined as the presence of cutaneous signs of dermatomyositis with no clinical evidence of muscle weakness for ≥ 6 months.
      • CADM affects 5–20% of patients with dermatomyositis and has a significant impact on quality of life.
      • There is no current consensus on the treatment of CADM and no previous systematic reviews have assessed this.

      What does this study add?

      • This systematic review has established that there are no randomized controlled trials or robust observational studies for treatment of CADM.
      • From the compilation of case series and reports, hydroxychloroquine is the most commonly prescribed treatment for CADM.
      • A proportion of patients have treatment-resistant disease.
      • In comparison with other treatments, intravenous immunoglobulin led to improvement or remission in the highest proportion of patients included in our review.
  75. Translational Research

    1. A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis

      T. Takahashi, Y. Asano, K. Nakamura, T. Yamashita, R. Saigusa, Y. Ichimura, T. Toyama, T. Taniguchi, A. Yoshizaki, Z. Tamaki, Y. Tada, M. Sugaya, T. Kadono and S. Sato

      Version of Record online: 30 AUG 2016 | DOI: 10.1111/bjd.14699

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • LL-37, an antimicrobial peptide, has been shown to be upregulated in systemic sclerosis dermal fibroblasts.
      • LL-37 potentially contributes to dermal fibrosis through its antiapoptotic effect on those cells.

      What does this study add?

      • LL-37 potentially contributes to the development of skin sclerosis, interstitial lung disease and digital ulcers in systemic sclerosis.
      • This further supports the critical role of antimicrobial peptides in the development of autoimmune and inflammatory diseases.

      What is the translational message?

      • LL-37 induction due to Fli1 deficiency in endothelial cells supports the notion that Fli1 deficiency is a key predisposing factor in the pathogenesis of systemic sclerosis.
      • This has recently been demonstrated by the establishment of a new systemic sclerosis animal model, with mice double heterozygous for the Klf5 and Fli1 genes.
  76. Research Letters

    1. Ulcerated infantile haemangiomas: the effect of the selective beta-blocker atenolol on wound healing

      G. Ruitenberg, D.A. Young-Afat, M. de Graaf, S.G.M.A. Pasmans and C.C. Breugem

      Version of Record online: 19 AUG 2016 | DOI: 10.1111/bjd.14687

      • image
  77. Case Reports

    1. Linear porokeratosis with multiple squamous cell carcinomas successfully treated by electrochemotherapy

      M. Sommerlad, A. Lock, G. Moir, J. McGregor, R. Bull, R. Cerio and C. Harwood

      Version of Record online: 17 AUG 2016 | DOI: 10.1111/bjd.14669

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Linear porokeratosis is a rare variant of porokeratosis thought to represent a mosaic form of disseminated superficial porokeratosis.
      • The diagnosis may be difficult to make. Patients are often initially diagnosed with variants of psoriasis or epidermal naevi.
      • Linear porokeratosis has the highest rate of malignant transformation. Treatment can be challenging due to the multiplicity and location of tumours.

      What does this study add?

      • This is the first report of multiple squamous cell carcinomas in the context of linear porokeratosis being successfully treated with electrochemotherapy (ECT).
      • ECT resulted in significant and sustained clearance of linear porokeratosis.
      • We illustrate the importance of multidisciplinary team input in the diagnosis and management of systematized linear porokeratosis.
  78. Research Letters

    1. Lysyl oxidase-like 2 promoter hypermethylation in mid-dermal elastolysis

      T. Gambichler, M. Skrygan, L. Reininghaus, H.-J. Schulze, J. Schaller, S. Hessam, C. Colato, G. Girolomoni and E. Heitzer

      Version of Record online: 17 AUG 2016 | DOI: 10.1111/bjd.14666

      • image
  79. Case Reports

    1. Late-onset cutaneous porphyria in a patient heterozygous for a uroporphyrinogen III synthase gene mutation

      P. Aguilera, C. Badenas, S.D. Whatley and J. To-Figueras

      Version of Record online: 11 AUG 2016 | DOI: 10.1111/bjd.14675

      • image
      • image
      • image

      What's already known about this topic?

      • Congenital erythropoietic porphyria (CEP) is an autosomal recessive disease due to the inheritance of mutations within the uroporphyrinogen III synthase (UROS) gene.
      • Heterozygous carriers do not present clinical or biochemical involvement.
      • Rare patients without UROS mutations have presented a CEP-like phenotype associated with myelodysplasia.

      What does this study add?

      • We report a unique case of a patient with late-onset cutaneous porphyria who was found to be a CEP carrier.
      • He presented a heterozygous germline mutation (C73R/wild-type) and sustained overproduction of type I porphyrin isomers.
      • With no evidence of myelodysplasia, acquired mosaicism is hypothesized as the origin of the atypical phenotype.
  80. Research Letters

    1. Written treatment plans in atopic eczema management in children

      C. Duhovic, M. Mohsin, E. Duarte-Williamson and S. Baron

      Version of Record online: 11 AUG 2016 | DOI: 10.1111/bjd.14651

      • image

VIEW

  1. 1 - 100
  2. 101 - 102

SEARCH

SEARCH BY CITATION